Biblio
A day 14 endpoint for acute GVHD clinical trials. Transplant Cell Ther. 2024.
Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms. Haematologica. 2024.
. Comparison of Pretransplant Prediction Models for Non-Relapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. Bone Marrow Transplant. 2023.
. . Clinical impact of KIR haplotypes in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2022:1-8.
Post-Transplant and In-Hospital Risk Factors for ARDS After Hematopoietic Stem Cell Transplantation. Respir Care. 2022.
. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients. Am J Hematol. 2022.
Risk Factors and Outcomes of Nocardiosis in Hematopoietic Stem Cell Transplant Recipients. Transplant Cell Ther. 2022.
. .
Chronic Graft-Versus-Host Disease in Pancreas After Kidney Transplant Recipients - An Unrecognized Entity. Am J Transplant. 2020.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplant. 2020.
Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. Transplantation. 2020.
Pre-transplant Risk Factors Can Predict Development of Acute Respiratory Distress Syndrome after Hematopoietic Stem Cell Transplantation. Ann Am Thorac Soc. 2020.
. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
15 Year Overall Survival Rates after Autologous Stem Cell Transplantation for AL Amyloidosis. Am J Hematol. 2019.
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034-4042.
Autologous stem cell transplant for AL amyloidosis patients aged 70 to 75. Biol Blood Marrow Transplant. 2018.
Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant. Hematol Oncol Stem Cell Ther. 2018.